Results 131 to 140 of about 517,948 (338)

A strategy to design protein-based antagonists against type I cytokine receptors.

open access: yesPLoS Biology
Excessive cytokine signaling resulting from dysregulation of a cytokine or its receptor can be a main driver of cancer, autoimmune, or hematopoietic disorders.
Timo Ullrich   +12 more
doaj   +1 more source

CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Defining the CSF cytokine/chemokine and injury biomarker signature of glial fibrillary acidic protein (GFAP) autoimmunity can inform immunopathogenesis. CSF GFAP‐IgG‐positive samples (N = 98) were tested for 17 cytokines/chemokines, neurofilament light chain (NfL), and GFAP (ELLA, Bio‐Techne).
Yahel Segal   +11 more
wiley   +1 more source

Cytokine and Cytokine Receptor Pleiotropy and Redundancy [PDF]

open access: yesJournal of Biological Chemistry, 2002
Warren J. Leonard, Katsutoshi Ozaki
openaire   +2 more sources

Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist

open access: bronze, 1994
John Mansfield   +7 more
openalex   +1 more source

Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Febrile infection related epilepsy syndrome (FIRES) is a rare presentation of refractory status epilepticus with immune dysregulation as a potential pathologic mechanism. Despite promising results from second‐line immunomodulators, approximately 30% remain refractory to treatment.
Kristen S. Fisher   +5 more
wiley   +1 more source

A common single nucleotide variant in the cytokine receptor-like factor-3 (CRLF3) gene causes neuronal deficits in human and mouse cells. [PDF]

open access: yesHum Mol Genet, 2023
Wilson AF   +12 more
europepmc   +1 more source

Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells

open access: hybrid, 1993
Alison Stopeck   +3 more
openalex   +1 more source

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy